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Summary The expression of P-glycoprotein in primary and recurrent human breast cancer was investigated
by means of immunohistochemistry, using a monoclonal antibody (C219) and the streptavidin-biotin-peroxi-
dase method. Twelve patients received no chemotherapeutic treatment. The other II patients were treated with
chemotherapy, and all developed clinical resistance to it. No or only minimal reactivity was found in
specimens coming from the untreated patients (12 cases) or from patients treated with substances not involved
in the multidrug resistance phenomenon (four cases). In contrast, three out of seven tumours from patients
treated with multidrug resistance related substances showed clear reactivity (positive staining in more than
20% of the tumour cells). In one of these cases, where specimens of the tumour could be studied before and
after treatment, an association between the latter and expression of P-glycoprotein was suggested. Finally, this
marked expression of P-glycoprotein only took place in tumours treated over a longer space of time (five
courses or more of multidrug resistance related chemotherapy).
During the past few years, we have begun to gain insight into
the mechanisms by which tumour cells become resistant to a
certain kind of chemotherapy (Moscow & Cowan, 1988;
Tsuruo, 1988). In this context, the connection between the
so-called 'multidrug resistance phenotype' (MDR) and the
expression of a 170 kDa membrane glycoprotein (usually
referred to as P-170 or P-glycoprotein) has been clearly
established in model tumours (Juliano & Ling, 1976; Kartner
et al., 1983; Volm et al., 1987). This membrane glycoprotein
acts as an energy-dependent pump, which actively extrudes
certain families of chemotherapeutic compounds from the
cells, to which these become cross-resistant. The agents
involved in this phenomenon are pharmacologically unre-
lated: hence the terms 'multidrug resistance' or 'pleiotropic
drug resistance' by which it is usually designated. Many of
these compounds, such as doxorubicin and its derivatives,
actinomycin-D or the vinca-alkaloids, are frequently used,
alone or in combination, for the treatment of a wide range of
tumours. It is therefore of importance for clinical practice to
elucidate whether human tumours under treatment with this
kind of chemotherapy actually develop the multidrug resis-
tance phenotype, and whether this had direct implications for
the development of clinical resistance to chemotherapy or
not. Such a relationship has been convincingly established for
model tumours under research conditions (Volm et al.,
1989a), where it was shown that only cells resistant to MDR
related chemotherapeutic agents developed the MDR pheno-
type, whereas the same cells made resistant against another
kind of chemotherapy did not.
We present a series of recurrent mammary carcinomas,
belonging to three different groups of patients from the same
clinic: patients without treatment, under observation after
radical mastectomy; patients under treatment with substances
unrelated to the multidrug resistance phenomenon; and
patients treated with multidrug resistance related chemo-
therapy. The expression of P-glycoprotein in the tumour cells
of the specimens from these patients was investigated by
means of immunohistochemistry, using a monoclonal anti-
body against P-glycoprotein (C219) and the streptavidin-
biotin-peroxidase method.
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Materials and methods
Tumours
The tumour specimens were obtained from patients operated
at the Department of Obstetrics and Gynaecology of the
Heidelberg University Clinic. They were immediately frozen
in liquid nitrogen at the time of operation and were kept at
- 70°C until they were used for the present investigation.
Twelve tumours were from untreated patients (five primary
tumours and seven local recurrences in patients under obser-
vation with no additional treatment after radical mastec-
tomy) (Table I). The other 11 tumours were from patients
clinically resistant to chemotherapy, i.e. with tumour pro-
gression or recurrence despite treatment.
Four of the patients were under treatment with substances
not related with multidrug resistance (which will be referred
to as non-MDR substances) at the time of operation. Two of
them were receiving tamoxifen alone, one a combination of
mitoxanthrone and prednisone (six courses) and one that
Table I Immunohistochemical detection ofP-glycoprotein expression in
breast cancer (MAB C219)
P-glycoprotein
Patient no. Therapy expression
1 none
2 none
3 none
4 none
5 none
6 none
7 none
8 none
9 none
10 none
11 none (+)
12 none (+)
13 CMF (6x), Mitoxanthrone + Prednisone (4x)
14 Mitoxanthrone + Prednisone (6x) (+)
15 Tamoxifen (2 years) (+)
16 Tamoxifen (2 years) (+)
17 VEC (2x)
18 FEC (2x)
19 VDS + MitC (2), VEC (2x) (+)
20 VEC(5x) (+)
21 E + Ifosfamide (2x), VDS + CDDP (3x) + +
22 FEC (8x) + +
23 E + Tamoxifen (12x) + +
CMF, cyclophosphamide, methothrexate, 5-fluorouracil; VEC, vincris-
tine, epirubicin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyc-
lophosphamide; VDS,vindesine, MitC,mitomicinC;E,epirubicin,CDDP,
cisplatin; -, no positive cells; ( + ), single positive cells; + + , more than
20% positive cells.
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same combination (four courses) followed by a combination
of cyclophosphamide, methothrexate and 5-fluorouracil
(CMF) for six courses.
Seven patients were under treatment with substances
involved in multidrug resistance (MDR substances). Two had
received epirubicin, in combination with cyclophosphamide
and 5-fluorouracil (FEC) (two and eight courses respect-
ively); two had been treated with epirubicin plus vicrinstine,
in combination with cyclophosphamide (VEC) (two and five
courses, respectively); one had received 12 courses of epiru-
bicin, in combination with tamoxifen; one had received two
courses of vindesine and mitomicin C, followed by another
two of VEC; and one had been treated with epirubicin, in
combination with ifosfamide (two courses), followed byvin-
desine plus cisplatin (three courses).
Cryostat sections of the tumour samples, 6 .tm thin, were
made. They were allowed to dry overnight, then fixed in cold
acetone (-20°C) and stored at -20°C until they were
examined.
Immunohistochemistry
The monoclonal antibody used for P-glycoprotein detection
was the C219 antibody originally developed by Kartner and
Ling. It recognises an epitope lying in a cytoplasmic domain,
200 amino acids long, of the C-terminal region of the P-
glycoprotein polypeptide (Kartner et al., 1985).
The sections were rehydrated in PBS and afterwards
quenched for the blocking of endogenous peroxidase activity
in 0.3% H202/methanol. The monoclonal first antibody
(C219; Centocor, Malvern, PA, USA) was then applied at a
concentration varying between 2.5 and 10 lg ml', and
incubated overnight at 4°C. Afterwards, the second
biotinylated antimouse antibody (Amersham) and the
streptavidin-biotinylated-peroxidase complex (Amersham)
were applied in successive steps. Staining was performed by
means of 3-amino-9-ethylcarbazole, giving a red-brown reac-
tion product. The preparations were finally counterstained
with Mayer's haematoxylin and mounted with glycerol
gelatin. Negative controls for each sample were performed by
incubation with normal mouse serum in substitution for the
first antibody, at the same concentration, the rest of the
procedure being carried out as described (Volm et al., 1988a).
As positive controls we used colchicine-resistant CHO cell
smears and preparations from a solid sarcoma-180 nude rat
xenograft resistant to daunorubicin, expressing high levels of
P-glycoprotein (Volm et al., 1988b, 1989b).
The preparations were evaluated independently by four of
the authors (M.V., M.B., J.M. and J.S.), without knowledge
of the clinical data, which were provided after the results of
the immunohistochemistry had been obtained.
Three distinct patterns of staining were encountered: no
positive cells at all; single, scattered positively staining
tumour cells; numerous (>20%) positive cells, evenly distri-
buted throughout the tumour.
Results
In the group of untreated breast tumours, or of breast
tumours under treatment with substances not related to
multidrug resistance, we found no case that was clearly
positive for P-glycoprotein (Table I). However, two out of 12
untreated tumours and three out of four treated with non-
MDR substances showed reactivity in single, isolated tumour
cells.
In the group of tumours from patients treated with MDR-
related substances, on the other hand, there were three
tumours which were clearly positive for P-glycoprotein, with
20% or more of the cells showing reactivity (Table I, Figure
1 al, a2, bl, b2). The intensity of the reaction was rather
uniform, and never as high as that found in the experimental
models used as positive controls (Figure 1, cl) but was
nevertheless quite distinct. These three patients had received
five, eight and 12 courses of MDR therapy, respectively, at
the time of operation. One of these recurrent tumours was
from a patient whose primary, untreated tumour could also
be analysed in this study, and was negative (Figure1 b3). A
relationship between MDR treatment, resistance and P-glyco-
protein expression seems thus to exist in this case. Of the
remaining four patients of this group, two had received only
two courses of treatment, and the other two had received
four and five courses, respectively. The tumours from these
patients contained only single, isolated positively staining
cells in two cases, and showed no reactivity at all in the other
two. Although the patient number is low, these results seem
to indicate that P-glycoprotein is expressed in this kind of
tumours at significant levels only after a certain amount of
MDR therapy has been delivered to them.
Discussion
Tumours arising in organs that normally express high levels
of P-glycoprotein, such as the kidney, the adrenal or the
colon (Thiebaut et al., 1987) are known to be intrinsically
resistant to chemotherapy. This indirectly supports the view
that P-glycoprotein may indeed play a role in the develop-
ment of resistance. As for tumours originating in other
tissues, with no original P-glycoprotein expression, there have
already been reports of isolated cases, suggested a relation-
ship between increasing levels of P-glycoprotein during treat-
ment, and the appearance of clinical resistance, e.g. in
ovarian carcinoma (Bell et al., 1985) and in leukaemia (Ma et
al., 1987).
The first case of detection of P-glycoprotein by means of
immunocytochemistry in a human breast tumour has been
reported by Sugawara et al. (1988), who studied the distri-
bution of P-170 in different normal human tissues and
tumours with the help of the monoclonal antibody MRK 16.
The first large study on human breast cancer and P-glyco-
protein expression has recently been published by Merkel et
al. (1988) who, using mRNA and DNA analysis, did not find
a single case of MDR gene amplification among 248 mam-
mary carcinomas, of which 22 were studied after induction
(non-MDR) chemotherapy and seven after adriamycin
therapy. RNA-analysis of 95 tumours from that same series
was also negative, although 13 patients had been treated with
regimens containing adriamycin. These results are in agree-
ment with our own experience using the 265/F4 monoclonal
antibody the authors used for selecting their cDNA clone.
We also found no positive reaction for P-glycoprotein when
using this monoclonal antibody on our mammary tumour
material, whereas it yielded the expected results with renal
tumours, normal kidney expressing high P-glycoprotein levels
(the positive control used by Merkel et al., 1988), normal
liver and human leukaemias (Volm et al., 1989b).
Goldstein et al. (1989) found nine positive cases, of which
two had been treated (kind of treatment not stated), among
57 breast cancers. They used the same methodology of
mRNA measurements as Merkel et al. (1988), who in their
paper make the comment that their approach cannot exclude
the existence of small tumour subpopulations expressing P-
glycoprotein and that, alternatively, monoclonal antibodies
directed against it could be used to detect P-glycoprotein by
immunohistochemistry. This is the approach we have chosen.
Our results demonstrate that immunocytochemistry may be a
useful method for the detection of P-glycoprotein in clinical
material. Determination of m-RNA contents (Merkel et al.,
1988; Goldstein et al., 1989) may be impractical in the
clinical setting for several reasons: it is technically more
cumbersome, implies the use of sophisticated laboratory
material not present in every hospital and is more time-
consuming. Finally, at the present moment, it is still unclear
whether only tumour cells express P-glycoprotein under treat-
ment, or if the tumour cells expressing it are the most
representative ones for the development of resistance to
chemotherapy (Chan et al., 1988). We found, for instance,
that ductal cells in a fibroadenomatous area immediately
adjacent to the tumour infiltrate in one case, and hyperplasticP-GLYCOPROTEIN AND BREAST CANCER 817
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Figure 1 P-glycoprotein reactivity with Mab C219, al: case no. 21. Positive reaction in tumour cells. Immunoperoxidase x 250.
a2: case no. 22. Positive reaction in tumour cells. Immunoperoxidase x 250. a3: negative control of specimen no. 22.
Immunoperoxidase x 250. bl: case no. 23. Positive reaction in tumour cells. Immunoperoxidase x 400. b2: case no. 23. Positive
reaction in tumour cells. Streptavidin-biotin-phycoerythrin x 400 (method according to Volm et al., 1989b). b3: case no. 7.
Negative primary tumour of case no. 23 (bI and b2) before MDR therapy. Immunoperoxidase x 250. cl: daunorubicin-resistant
Sal80 nude rat xenografts used as positive control. Immunoperoxidase x 250. c2: case no. 14. Positive reaction in normal ductal
cells. Immunoperoxidase x 250. c3: case no. 12. Positive reaction in hyperplastic ductal cells. Immunoperoxidase x 250.
ductal cells in another, expressed P-glycoprotein, whereas the
tumour cells themselves did not (Figure 1 c2, c3), a finding
that would possibly produce a false-positive result if the same
specimens were analysed for m-RNA content. We also had
difficulties in attributing any significance to the described
pattern of only single tumour cells staining positively for
P-glycoprotein in a specimen. At the present state of know-
ledge we believe that, for practical purposes, these tumours
probably should be considered negative. Another finding that
caused interpretative trouble was the cytoplasmic staining
consistently found in positive cells, although the controls
performed in parallel with the reaction ruled out the possi-
bility of unspecific staining. Recently, cytoplasmic P-glyco-
protein staining has been reported as a normal finding in
multidrug resistant cells at low degrees of resistance (4-6-
fold), using a monoclonal antibody (JSB1) that recognises an
epitope on the same narrow cytoplasmic domain as the one
recognised by C219 (Broxterman et al., 1989). A higher than
10-fold resistance had to be reached in their model tumour
cells, before the observed reaction was distinctly membrane
bound. Such levels of resistance was probably never reached
in humans. Nevertheless, immunofluorescence was able to
show in our material that P-glycoprotein is detected mainly
on the membrane, even if this is not so apparent in the
corresponding immunohistochemical preparation. The results
we present also speak in favour of a possible relationship
between treatment with multidrug resistance related chemo-
therapy and the expression of P-glycoprotein in human
(mammary) tumours, similar to that found in experimental
models (Volm et al., 1989a). The one case of this study where
P-glycoprotein and clinical resistance appeared in parallel
fashion, and the fact that our clearly positive cases were to
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be found only in the patient group having received MDR
therapy in high doses, favour such a hypothesis. The
presence of two control groups, one without any treatment
and one with non-MDR treatment, where P-glycoprotein was
not detected at any significant levels, validates this result.
Its confirmation in larger series and for other tumours
would open the possibility for including P-glycoprotein deter-
minations into the planning scheme of tumour therapy. By
detecting those tumours which express P-glycoprotein
primarily, useless treatment with MDR chemotherapy could
be avoided. There is also evidence that the functioning of
P-glycoprotein can be effectively modulated by means of
certain substances, notably verapamil, trifluoperazine and
other membrane-active compounds, although the high doses
necessary for obtaining this effect experimentally still prec-
lude their use in patients (Tsuruo et al., 1987).
In conclusion, P-glycoprotein is demonstrable in human
mammary carcinomas by means of immunohistochemistry; it
was present at clearly detectable levels only after treatment
with chemotherapeutic substances related to the multidrug
resistance phenomen; finally, its appearance may be related
with the development of tumour resistance to MDR therapy.
This method may prove to be of use in the future for clinical
practice.
J. Schneider is the recipient of a grant from the Spanish Social
Security Investigation Fund.
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